First In Human Study of CX-2051 in Advanced Solid Tumors

Part of paid clinical trials in Denver, Colorado.

Sponsor
CytomX Therapeutics
Study ID
NCT06265688
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CX-2051 — DRUG
    Investigational drug
  • Bevacizumab — DRUG
    IV infusion

Study Details

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Key Dates

Start date
Apr 2, 2024
Status verified
May 2026
Primary completion
Nov 30, 2027
Completion
Mar 31, 2029

Study Design

Enrollment
160 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: CX-2051
  • Experimental: CX-2051 + bevacizumab

Primary Outcome Measure

Safety and tolerability of CX-2051 [ Time Frame: 44 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research Institute at HealthONEDenverColorado80218-
Dana-Farber Cancer InstituteBostonMassachusetts02215-
Montefiore Medical CenterThe BronxNew York10461-
Carolina BioOncology Institute, PLLCHuntersvilleNorth Carolina28078-
Sarah Cannon Research Institute, LLCNashvilleTennessee37203-
START San Antonio LLCSan AntonioTexas78229-
NEXT VirginiaFairfaxVirginia22031-

Find similar trials in Denver, CO

By research site
Sarah Cannon Research Institute at HealthONE· Denver, CODana-Farber Cancer Institute· Boston, MAMontefiore Medical Center· The Bronx, NYCarolina BioOncology Institute, PLLC· Huntersville, NCSarah Cannon Research Institute, LLC· Nashville, TNSTART San Antonio LLC· San Antonio, TX

Related Studies